Hermetica Superfood Encyclopedia
The Short Answer
Cassia fistula contains anthraquinones—including chrysophanol, physcion, rhein, and fistulic acid—alongside flavonoids such as biochanin A, which act as free radical scavengers, COX-2 inhibitors, and antimicrobial agents through disruption of bacterial cell function and modulation of inflammatory enzyme pathways. Preclinical data show antibacterial minimum inhibitory concentrations as low as 94 μg/mL against Staphylococcus epidermidis and DPPH radical scavenging activity with concentration-dependent efficacy, though no large-scale human clinical trials have yet validated these effects.
CategoryHerb
GroupSoutheast Asian
Evidence LevelPreliminary
Primary Keywordcassia fistula benefits
Golden Shower Tree — botanical close-up
Health Benefits
**Laxative and Gastrointestinal Support**
Anthraquinones in the fruit pulp—particularly rhein and chrysophanol—stimulate intestinal peristalsis, making Cassia fistula a traditional cathartic used in Ayurveda and Thai medicine for constipation relief.
**Antibacterial Activity**
Ethanol leaf extracts demonstrated inhibition zones up to 24 mm against Staphylococcus epidermidis and MIC values of 94–1500 μg/mL across multiple Gram-positive and Gram-negative bacteria, suggesting broad-spectrum antimicrobial potential.
**Antioxidant Protection**
Seed extracts scavenge DPPH free radicals in a concentration-dependent manner; nanoparticle formulations of seed extract showed inhibition zones of 11–20 mm against E. coli and S. aureus at 0.125–1 mg/mL, reflecting dual antioxidant and antimicrobial capacity.
**Anti-inflammatory Effects**
Molecular docking studies identify key compounds as COX-2 inhibitors, and phenolic-rich fractions reduce inflammatory signaling in vitro, supporting the traditional use of bark and leaf preparations for skin inflammation and dermatological conditions.
**Antileishmanial Potential**
Biochanin A isolated from fruit dichloromethane extract inhibits Leishmania chagasi promastigote growth with an EC50 of 18.96 μg/mL, indicating selective antiprotozoal activity relevant to tropical infectious disease contexts.
**Antidiabetic Mechanisms**
In silico docking analyses suggest phytoconstituents interact with GLUT-3 glucose transporters, potentially modulating glucose uptake, though this mechanism has not been confirmed in vivo or in human trials.
**Skin Disease Management**
Traditional applications in Thai and Indonesian medicine use bark and leaf preparations topically for fungal infections, eczema, and wound healing, supported by in vitro antimicrobial data though clinical dermatological trials remain absent.
Origin & History
Natural habitat
Cassia fistula L. is native to the Indian subcontinent and Southeast Asia, thriving in tropical and subtropical climates across Thailand, Indonesia, Sri Lanka, and Myanmar, where it is cultivated as both an ornamental and medicinal tree. It grows well in well-drained soils at low to moderate altitudes and tolerates seasonal drought. The tree is the national flower of Thailand (known as 'dok khuen') and has been integrated into traditional medicine across South and Southeast Asian cultures for centuries.
“Cassia fistula has been documented in Ayurvedic texts for over two millennia under the Sanskrit name 'Aragvadha,' meaning 'disease killer,' where it was classified as a gentle purgative (mridu virechana) and used to treat skin disorders, fever, and constipation. In Thai traditional medicine, the tree—known as 'Ratchaphruek' and serving as Thailand's national emblem—holds deep cultural and ceremonial significance, with its bright yellow flowers associated with Thai royalty, while its pods and bark are employed in folk remedies for dermatoses and gastrointestinal complaints. Indonesian Jamu traditional medicine similarly incorporates Cassia fistula bark and leaf preparations for inflammatory skin conditions and as a general tonic. The plant's dual identity as both a sacred ornamental species and a pharmacopeial ingredient across Unani, Ayurvedic, and Southeast Asian healing traditions reflects centuries of empirical use that now underpins modern phytochemical investigation.”Traditional Medicine
Scientific Research
The current evidence base for Cassia fistula consists entirely of in vitro antibacterial and antioxidant assays, callus culture phytochemical analyses, molecular docking simulations, and nanoparticle formulation studies—with no published human randomized controlled trials identified in the available literature. Antibacterial studies report MIC values of 94–1500 μg/mL and inhibition zones of 11–24 mm against common pathogens including S. epidermidis, B. subtilis, E. coli, P. aeruginosa, S. aureus, and S. pyogenes, demonstrating consistent in vitro efficacy across solvent extracts and nanoparticle formulations. Anthraquinone quantification in callus cultures reached 170 mg/100 g fresh weight comprising eight derivatives, and rhein was detected at 0.0084–0.0257% in bark and small branches respectively. The evidence base is preclinical in nature, and while mechanistically plausible, translation to human clinical outcomes remains unestablished; independent replication across diverse populations and rigorous pharmacokinetic studies are necessary before therapeutic claims can be substantiated.
Preparation & Dosage
Traditional preparation
**Traditional Fruit Pulp Decoction**
5–15 g of pulp
Aqueous decoction of ripe fruit pods used as a laxative in Ayurvedic practice; no standardized human dose established, historically administered as .
**Ethanol Leaf Extract**
6 mg/g of powdered leaf; used in research at 0
Yields the highest phytochemical concentration at 158..125–1 mg/mL for antimicrobial testing—human-equivalent dosing is not established.
**Aqueous Seed Extract**
125–1 mg/mL for antibacterial activity; no oral supplement dose defined
Used to synthesize nanoparticles in research; hot aqueous preparation tested at 0..
**Bark Decoction**
Traditional Thai and Indonesian skin disease treatment applied topically as aqueous or ethanolic extracts; standardization to rhein content (0.0084–0.0257%) has been proposed analytically but not commercially implemented.
**Standardized Extract (Anthraquinones)**
170 mg anthraquinones/100 g fresh weight; no commercial supplement with defined anthraquinone standardization is currently widely available
Callus cultures yield .
**Timing Note**
Traditional laxative preparations are typically consumed at night to allow overnight intestinal transit; no pharmacokinetic data define optimal timing for other proposed uses.
Nutritional Profile
Cassia fistula does not constitute a significant dietary food source and therefore lacks a conventional macronutrient profile; its pharmacological relevance derives from secondary metabolites rather than primary nutrients. Key phytochemicals include anthraquinones (170 mg/100 g in callus tissue; rhein at 0.0084–0.0257% in bark fractions), flavonoids including biochanin A (EC50 18.96 μg/mL antileishmanial activity), tannins, saponins, alkaloids, glycosides, and triterpenoids concentrated predominantly in polar ethanol and methanol extracts (up to 158.6 mg/g powdered leaf). Polyphenolic and phenolic compound content supports peroxidase enzymatic activity in plant tissues. Bioavailability of anthraquinones from plant matrices is influenced by solvent polarity of extraction, gut microbiome conversion of glycoside forms to active aglycones, and intestinal transit time; no human pharmacokinetic data for Cassia fistula constituents are currently published.
How It Works
Mechanism of Action
Anthraquinones such as rhein and chrysophanol intercalate with bacterial DNA and disrupt cell membrane integrity, while also stimulating colonic motility via direct irritation of the intestinal mucosa and inhibition of electrolyte reabsorption—the primary laxative mechanism. Flavonoid biochanin A and polyphenolic compounds function as free radical scavengers by donating hydrogen atoms to stabilize reactive oxygen species, with peroxidase enzyme activity shown to increase in phenolic-rich callus tissues. Molecular docking studies indicate that multiple phytoconstituents competitively inhibit COX-2 (cyclooxygenase-2), reducing prostaglandin synthesis and downstream inflammatory cascades, and may interact with GLUT-3 transporter proteins to modulate cellular glucose uptake relevant to antidiabetic activity. Additionally, inhibition of cytochrome P450 3A4 (CYP3A4) enzyme activity by Cassia fistula constituents has been predicted in silico, which would slow hepatic metabolism of CYP3A4 substrate drugs such as amlodipine, elevating their plasma concentrations.
Clinical Evidence
No human clinical trials have been conducted or reported in the accessible literature for Cassia fistula supplementation or extract therapy. All quantified outcomes derive from in vitro cell-free assays, microbial inhibition experiments, and computational docking models rather than controlled human studies. Preclinical endpoints such as DPPH scavenging concentration-response, bacterial MIC/MBC values, and docking binding affinities provide mechanistic hypotheses but cannot be directly extrapolated to clinical effect sizes or therapeutic doses in humans. Confidence in clinical efficacy is therefore very low, and the ingredient's traditional use as a laxative in Ayurveda and Southeast Asian medicine represents the strongest real-world validation currently available.
Safety & Interactions
Cassia fistula contains stimulant laxative anthraquinones structurally similar to those in senna (Cassia senna), raising analogous concerns about chronic use leading to electrolyte imbalance, potassium depletion, and laxative dependence with prolonged administration—though specific toxicity thresholds for this species have not been formally established. A significant predicted drug interaction involves CYP3A4 enzyme inhibition, which could elevate plasma concentrations of substrate medications including calcium channel blockers (e.g., amlodipine), statins, immunosuppressants, and certain antiretrovirals, potentially intensifying pharmacological and adverse effects. No formal contraindication data exist for pregnancy or lactation, but stimulant anthraquinone-containing herbs are generally contraindicated in pregnancy due to potential uterotonic activity and electrolyte risks during breastfeeding. Nanoparticle formulations showed no hemolytic activity in preclinical hemocompatibility testing; however, comprehensive in vivo toxicology and maximum tolerated dose studies in humans are absent, and caution is warranted until such data are available.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Cassia fistula L.Golden Shower TreeAragvadhaRatchaphruekPurging CassiaIndian LaburnumDok Khuen
Frequently Asked Questions
What is Cassia fistula used for medicinally?
Cassia fistula is used primarily as a natural laxative and for treating skin diseases in Thai, Indonesian, and Ayurvedic medicine, leveraging its anthraquinone content—particularly rhein and chrysophanol—to stimulate intestinal motility. It is also studied for antibacterial activity, with ethanol leaf extracts showing MIC values as low as 94 μg/mL against S. epidermidis, and for anti-inflammatory effects attributed to COX-2 inhibition by its phenolic and flavonoid compounds.
Does Cassia fistula have any proven clinical benefits in humans?
No published human clinical trials have evaluated Cassia fistula supplementation with defined sample sizes or measured clinical endpoints; all quantified benefit data come from in vitro antimicrobial assays, DPPH antioxidant tests, and computational docking models. Its clinical use rests on centuries of traditional practice in Ayurveda and Southeast Asian medicine, particularly for constipation and dermatological conditions, rather than controlled human trial evidence.
Are there any drug interactions with Cassia fistula?
Cassia fistula constituents are predicted to inhibit the CYP3A4 hepatic enzyme based on in silico docking studies, which could increase plasma levels of CYP3A4-metabolized drugs such as amlodipine, potentially enhancing its blood pressure-lowering effect and risk of hypotension. Patients taking calcium channel blockers, statins, immunosuppressants, or other CYP3A4 substrates should consult a healthcare provider before using Cassia fistula preparations, as formal pharmacokinetic interaction studies in humans have not yet been conducted.
What are the main bioactive compounds in Cassia fistula?
The primary bioactive compounds are anthraquinones—including chrysophanol, physcion, rhein, and the species-specific fistulic acid—present at concentrations of approximately 170 mg/100 g in callus cultures and 0.0084–0.0257% rhein in bark fractions. Flavonoids, particularly biochanin A (EC50 of 18.96 μg/mL against Leishmania chagasi), tannins, saponins, alkaloids, and triterpenoids are also present, with polar solvents like ethanol extracting the highest yields at up to 158.6 mg/g of powdered leaf.
Is Cassia fistula safe to use, and what are the side effects?
Cassia fistula contains stimulant anthraquinone laxatives similar to senna, which with chronic use can cause electrolyte imbalances, potassium depletion, and laxative dependency—though species-specific toxicity thresholds in humans have not been formally determined. It is generally advisable to avoid use during pregnancy due to potential uterotonic anthraquinone activity, and caution is warranted in individuals taking CYP3A4-metabolized medications; comprehensive human safety studies are lacking, making it premature to define a maximum safe dose.
What is the most effective form of Cassia fistula for constipation relief?
The fruit pulp extract is the most traditionally used and studied form, as it contains the highest concentration of anthraquinones like rhein and chrysophanol that stimulate intestinal peristalsis. Standardized extracts or dried pulp preparations tend to offer more consistent potency than whole fruit products. The liquid or powder forms allow for easier dosage adjustment compared to solid preparations.
Is Cassia fistula safe to use during pregnancy or while breastfeeding?
Cassia fistula is traditionally contraindicated during pregnancy due to its strong laxative properties and potential stimulant effects on uterine muscle. Women who are breastfeeding should also avoid it, as anthraquinone metabolites may pass into breast milk and affect the infant. Medical consultation is strongly recommended before use in these populations.
How does Cassia fistula compare to other herbal laxatives like senna or aloe vera?
Cassia fistula works similarly to senna through anthraquinone-mediated peristalsis stimulation but is often considered gentler and less likely to cause cramping. Unlike aloe vera, which acts more quickly, Cassia fistula typically takes 6–12 hours for effect, making it suitable for overnight use. Cassia fistula also has documented antibacterial properties in traditional medicine that senna and aloe vera do not emphasize as prominently.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w cassia-fistula-cassia-fistula-l curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
